Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has reported encouraging early progress in the US commercial rollout of its FebriDx® rapid respiratory infection test following recent FDA CLIA waiver clearance, with reimbursement performance and customer adoption tracking positively ahead of the 2026/27 flu season.
The company said more than 90% of submitted reimbursement claims had been paid to date, with average payments exceeding the Medicare fee schedule benchmark of US$41.38 per test.
Lumos is using the current lower-volume spring and summer testing period in the US to build market awareness, onboard customers, progress pilot evaluations and refine reimbursement pathways in CLIA-waived settings.
“Securing CLIA waiver was a major step forward, but successful commercialisation also depends on showing that providers can implement FebriDx® routinely and receive payment for its use. While these reimbursement datasets are still in their infancy and not yet statistically significant, we are very pleased with the initial signals. They support the view that FebriDx® can be embedded into routine workflows in urgent care and primary care, particularly as providers prepare for the next flu season,” Lumos CEO Doug Ward said.
Early commercial rollout advances
FebriDx is now in routine use across 44 WellStreet Urgent Care clinics, providing Lumos with an important early commercial reference point within WellStreet’s broader network of around 165 locations.
The company is also progressing pilot programs with eight additional urgent care chains operated by new ownership groups, with evaluations and implementation activities advancing favourably.
Lumos said these early installations were helping establish its footprint ahead of the next northern hemisphere flu season, while also supporting broader pipeline development across the US urgent care market.
The company intends to continue updating investors as additional commercial opportunities advance.
Reimbursement tracking above benchmark
Lumos said reimbursement remains a critical component of successful US commercialisation and noted that FebriDx has a dedicated Proprietary Laboratory Analyses (PLA) code, 0442U, carrying a Medicare fee schedule rate of US$41.38 per test.
The company has been monitoring reimbursement trends through consultants PRO-spectus and AcuityMD and has started receiving initial payment data from active sites.
While Lumos cautioned the sample size remains small and not yet statistically significant, management said the early reimbursement trends were encouraging.
In addition to the more than 90% claim payment rate, the company said average payments received were above the Medicare benchmark, supporting its strategy to drive adoption across urgent care and primary care settings where providers require both clinical utility and reimbursement certainty.
Building foundations ahead of flu season
Lumos said its current focus remained on establishing the commercial foundations needed for broader uptake ahead of the 2026/27 US flu season.
This includes supporting customers with reimbursement education, claims optimisation and workflow integration as payer pathways continue to mature.
These early commercial and reimbursement outcomes position FebriDx favourably as adoption expands across the US respiratory diagnostics market.